Longitudinal Clinical Course, Treatment Outcomes, and Relapse Patterns in Alopecia Areata: A Prospective Cohort Study

    November 2025 in “ Frontiers in Medicine ”
    Wenjie Yan, Yue Wang, Mengjiao Wang … Xi Huang
    Studysummary In this prospective cohort, baseline severity, disease activity, and relapse history were identified as key factors influencing response and recurrence in alopecia areata, suggesting that implementing standardized assessments could enhance risk stratification and personalized care approaches.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on public-pages-files-2025.frontiersin.org →
    Discuss this study in the Community →

    Research cited in this study 33

    1. Global Burden of Alopecia Areata from 1990 to 2019 and Emerging Treatment Trends Analyzed Through GBD 2019 and Bibliometric Data Scientific Reports · 2025
    2. Immune-Mediated Disorders in Patients With Alopecia Areata: Systematic Review and Meta-Analysis International Journal of Dermatology · 2025
    3. Lessons from TNF-Alpha Inhibitor-Induced Alopecia Areata: Does TNF-Alpha Operate as a Hair Follicle Immune Privilege Guardian Under Inflammatory Conditions? Journal of Investigative Dermatology · 2025
    4. Predominance of CD27-PD-1- Effector Memory T Cells Re-Expressing CD45RA Characterizes Treatment-Resistant Severe Alopecia Areata Journal of Investigative Dermatology · 2025
    5. Serum-Based Assessment of Alopecia Areata Response to Treatment Using ATR-FTIR Spectroscopy Diagnostics · 2025
    6. Innovative Approaches to the Assessment of Alopecia Areata: Incorporating the SALT Index Through Transparent Devices International Journal of Dermatology · 2025
    7. SALT Score Distribution With Ritlecitinib Treatment Up to 24 Months in Alopecia Areata Journal of the European Academy of Dermatology and Venereology · 2025
    8. Real-World Evidence for Baricitinib in the Treatment of Atopic Dermatitis and Alopecia Areata: Systematic Literature Review 2020–2023 Dermatology and Therapy · 2025
    9. Unveiling the Immune and Vitamin Profiles of Blood: Potential Biomarkers for Alopecia Areata PeerJ · 2025
    10. Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment American Journal of Clinical Dermatology · 2025
    11. Evaluation of SALT Score Severity in Correlation With Trichoscopic Findings in Alopecia Areata: A Study of 303 Patients Archives of Dermatological Research · 2025
    12. Switching JAK Inhibitors: Evaluating Baricitinib’s Effectiveness in Alopecia Areata After Tofacitinib Failure Archives of Dermatological Research · 2025
    13. Dual Improvement of Alopecia Areata and Immune Thrombocytopenia With Baricitinib: A Case Report Skin Health and Disease · 2025
    14. Identifying Effective Immune Biomarkers in Alopecia Areata Diagnosis Based on Machine Learning Methods BMC Medical Informatics and Decision Making · 2025
    15. Complete Responses And SALT Zero Scores In Alopecia Areata: Not The Same Journal of Dermatological Treatment · 2024
    16. Predictors And Management Of Inadequate Response To JAK Inhibitors In Alopecia Areata American Journal of Clinical Dermatology · 2024
    17. Comparative Efficacy and Safety of Systemic Steroids, Oral JAK Inhibitors, and Contact Immunotherapy in the Treatment of Severe Alopecia Areata: A Systematic Review and Network Meta-Analysis Archives of Dermatological Research · 2024
    18. A Review of JAK Inhibitors for Treatment of Alopecia Areata in the Military Health Care System Military medicine · 2024
    19. Retracted: Causal Role of Immune Cells in Alopecia Areata: A Two-Sample Mendelian Randomization Study Skin Research and Technology · 2024
    20. Construction of Regulatory Network for Alopecia Areata Progression and Identification of Immune Monitoring Genes Based on Multiple Machine-Learning Algorithms Precision clinical medicine · 2023
    21. Trends in Prevalence and Incidence of Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Among Adults and Children in a US Employer-Sponsored Insured Population JAMA Dermatology · 2023
    22. Prevalence of Alopecia Areata in Japan: Estimates from a Nationally Representative Sample The Journal of Dermatology · 2022
    23. Prevalence, Comorbidities, and Treatment Patterns of Japanese Patients with Alopecia Areata: A Descriptive Study Using Japan Medical Data Center Claims Database The Journal of Dermatology · 2022
    24. Alopecia Areata as an Immune-Related Adverse Event Associated with Response to Immune Checkpoint Inhibitors European Journal of Dermatology · 2022
    25. Prevalence and Risk Factors Associated with the Occurrence of Autoimmune Diseases in Patients with Alopecia Areata Journal of Inflammation Research · 2021
    26. Tofacitinib for the Treatment of Three Immune-Mediated Conditions in One Patient: Ulcerative Colitis, Pyoderma Gangrenosum, and Alopecia Areata Inflammatory Bowel Diseases · 2021
    27. A Large Cross-Sectional Survey Study of the Prevalence of Alopecia Areata in the United States Clinical Cosmetic and Investigational Dermatology · 2020
    28. Epigallocatechin-3 Gallate Inhibits STAT-1/JAK2/IRF-1/HLA-DR/HLA-B and Reduces CD8 NKG2D Lymphocytes in Alopecia Areata Patients International journal of environmental research and public health/International journal of environmental research and public health · 2018
    29. High-Throughput T Cell Receptor Sequencing Identifies Clonally Expanded CD8+ T Cell Populations in Alopecia Areata JCI insight · 2018
    30. Quantifying Alopecia Areata via Texture Analysis to Automate the SALT Score Computation Journal of Investigative Dermatology Symposium Proceedings · 2017
    31. SOCS3 Treatment Prevents the Development of Alopecia Areata by Inhibiting CD8+ T Cell-Mediated Autoimmune Destruction Oncotarget · 2017
    32. CD8-Positive Mycosis Fungoides Clinically Masquerading as Alopecia Areata Journal of Cutaneous Pathology · 2016
    33. Human Leukocyte Antigen Class II Alleles Are Associated with Risk of Alopecia Areata Journal of Investigative Dermatology · 2007